Barclays
TOVX icon

Barclays’s Theriva Biologics TOVX Stock Holding History

Barclays’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-32,569
Closed -$6.85K – 5439
2025
Q4 		$6.85K Buy
+32,569
New +$9.63K ﹤0.01% 4968
2024
Q4 		– Sell
-495
Closed -$683 – 5477
2024
Q3 		$683 Buy
+495
New +$2.42K ﹤0.01% 5135
2021
Q4 		– Hold
0
– – – 4735
2021
Q3 		– Hold
0
– – – 5016
2021
Q2 		– Sell
-2
Closed – – 5079
2021
Q1 		$0 Buy
+2
New +$395 ﹤0.01% 5189
2018
Q2 		– Hold
0
– – – 7283
2018
Q1 		– Hold
0
– – – 7332
2017
Q3 		– Sell
-13
Closed -$62K – 7047
2017
Q2 		$62K Buy
13
+11
+550% +$54.8K ﹤0.01% 5229
2017
Q1 		$11K Buy
+2
New +$14K ﹤0.01% 6055
2016
Q4 		– Hold
0
– – – 6494
2016
Q3 		– Hold
0
– – – 6447

Other funds holding TOVX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Barclays's TOVX Position: Q1 2026 in Review

Barclays sold out of Theriva Biologics (TOVX) in Q1 2026, closing a stake of 32,569 shares — an estimated $6.85K sold.

Barclays first reported a position in TOVX in Q1 2017 and held it in 5 quarters. The position peaked at $62K in Q2 2017. 22 funds tracked by Wall St. Rank hold TOVX as of Q1 2026.

  • Barclays reported no remaining Theriva Biologics position as of Q1 2026 after selling out during the quarter.
  • Barclays sold 32,569 Theriva Biologics shares in Q1 2026, an estimated $6.85K.
  • Barclays first reported a position in Theriva Biologics in Q1 2017 and held it in 5 quarters.
  • Barclays's Theriva Biologics position peaked at $62K in Q2 2017.
  • 22 funds tracked by Wall St. Rank held Theriva Biologics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.